Annual Product Review (APR) Workflow

21 CFR 211.180(e)  |  EU GMP Chapter 1 (PQR)  |  ICH Q10
21 CFR 211.180(e)  ·  EU GMP Chapter 1
Product Quality Review  ·  ICH Q10
The APR looks backward across a year
to confirm the process is still in control
Phase 1 - Data Collection and Scope Definition
Phase 2 - Data Compilation and Trend Analysis
Phase 3 - Evaluation and Conclusion
Phase 4 - Reporting, CAPA, and Follow-Up
Decision point
GMPify Procedural Map Series
📄

Annual Product Review - The Yearly Check That the Process Still Holds

21 CFR 211.180(e) requires a written review of records for each drug product at least annually, evaluating quality standards to determine the need for changes to specifications or manufacturing or control procedures. The EU equivalent, the Product Quality Review under GMP Chapter 1, covers substantially the same ground with somewhat more prescriptive content requirements. The APR pulls together an entire year of otherwise separate data streams, batch disposition, deviations, complaints, stability, and change control, into a single coherent picture of whether the product and its process remain in a validated state of control.

21 CFR 211.180(e)  ·  EU GMP Chapter 1  ·  ICH Q10
21 CFR 211.180(e)
EU GMP Chapter 1 (PQR)
ICH Q10

Batch Release and Rejection Data

Every batch manufactured during the review period, its disposition, and any rejection or rework, compiled to establish overall batch performance.

Source: Batch records, QA release log

Complaint and Recall Data

All product complaints received during the period, along with any recall or field action, summarized by type and outcome.

Source: Complaint file, recall records

Deviation and OOS/OOT Data

All deviations, out-of-specification results, and out-of-trend findings for the product across the review period.

Source: QMS deviation and investigation log

Stability and Change Control Data

Ongoing stability programme results and all changes implemented affecting the product during the review period.

Source: Stability programme, change control log
Phase 1
Data Collection and Scope Definition
1Define the review period and product scope
Twelve-month review period defined, typically aligned to calendar or fiscal year, with the specific product or product family in scope clearly identified.
21 CFR 211.180(e)
2Identify all applicable data sources
Every data source required by 21 CFR 211.180(e) and applicable internal procedure identified and confirmed accessible before compilation begins.
21 CFR 211.180(e)
3Assign cross-functional responsibility
Data compilation responsibilities assigned across quality, manufacturing, and other relevant functions, reflecting that no single function holds every required data stream.
ICH Q10
4Confirm data completeness
Compiled data checked for completeness against the full review period before analysis begins, since a gap in the underlying data undermines the entire review's conclusions.
21 CFR 211.180(e)
Phase 2
Data Compilation and Trend Analysis
5Compile batch disposition data
Total batches manufactured, released, rejected, and reworked during the period compiled, with rejection rate calculated and compared against prior periods.
21 CFR 211.180(e)
6Compile quality event data
Deviations, OOS, OOT findings, and complaints compiled and categorized by type, providing the basis for trend analysis in the next phase.
21 CFR 211.180(e)
7Compile stability and change control data
Ongoing stability results and implemented changes compiled, with any stability trend or change-related quality impact flagged for closer evaluation.
21 CFR 211.166 · 211.180(e)
Do compiled trends indicate a need for further investigation?
YES → Escalate for focused review NO → Proceed to evaluation
Phase 3
Evaluation and Conclusion
8Evaluate against the prior year's APR
Current period trends compared against the prior APR to identify whether performance is improving, stable, or declining year over year.
ICH Q10
9Assess adequacy of specifications and controls
Current specifications, in-process controls, and manufacturing procedures assessed for continued adequacy in light of the year's actual performance data.
21 CFR 211.180(e)
10Draw conclusions on state of control
Formal conclusion drawn regarding whether the product and process remain in a validated state of control, supported by the compiled evidence.
ICH Q10
Phase 4
Reporting, CAPA, and Follow-Up
11Compile and approve the formal report
Written APR report compiled covering all required elements and formally approved by the quality unit before distribution.
21 CFR 211.180(e)
12Initiate CAPA for adverse trends
Corrective and preventive actions initiated for any adverse trend or conclusion identified during the review, tracked through the site's standard CAPA system.
ICH Q10
13Track CAPA and carry forward open items
CAPA tracked to closure, with any items still open at year-end carried forward and explicitly referenced in the following year's APR.
ICH Q10
Required APR Content (21 CFR 211.180(e))

Records Reviewed for Quality Standards

A written review of records for each drug product to evaluate quality standards, identifying the need for changes in specifications or manufacturing or control procedures.

21 CFR 211.180(e)

Minimum Annual Frequency

Review conducted at least annually, with each product reviewed on its own schedule rather than all products reviewed simultaneously on a single fixed calendar date.

21 CFR 211.180(e)

Change Justification Basis

The review's findings serve as the documented basis for determining whether any change to specifications or procedures is warranted going forward.

21 CFR 211.180(e)

Adverse Trend Response Steps

Step 1 - Characterize the trend clearly Describe precisely what is trending adversely, whether rejection rate, a specific deviation category, or a complaint type.
Step 2 - Determine whether the trend was previously known Check whether this trend was already flagged through routine trending outside the APR cycle, or whether it is a new finding.
Step 3 - Assess root cause at the annual level Investigate whether a systemic factor, rather than isolated individual events, is driving the year-over-year pattern.
Step 4 - Initiate CAPA with defined ownership Open a formal CAPA with a clearly assigned owner and target timeline, distinct from any individual event-level CAPA already in place.
Step 5 - Define success criteria for the next cycle Establish what improvement would look like by the next APR cycle, giving the following year's review a clear basis for assessing whether the action was effective.

Data Source Requirements

Complete period coverage Data spanning the entire twelve-month review period without gaps, even where responsibility for different data streams sits with different functions.
Consistent categorization Deviation, complaint, and other event categories applied consistently year over year, supporting genuine trend comparison rather than an apples-to-oranges review.
Traceable source records Every summarized figure in the APR traceable back to its underlying source record, supporting verification during an inspection.
Prior year cross-reference Current period data presented alongside, or explicitly compared to, the prior year's figures to make genuine trend evaluation possible.

APR / PQR Related Review Elements

Returned and Salvaged Goods Product returns and any salvage activity during the period reviewed for quality implications, consistent with EU GMP Chapter 1 expectations.
Post-Marketing Commitments Status of any post-marketing regulatory commitments related to the product tracked as part of the annual review.
Regulatory Variation Tracking Regulatory filings, variations, or amendments submitted for the product during the period cross-referenced against the review.
Equipment and Utility Qualification Status Qualification status of equipment and utilities supporting the product's manufacture confirmed current as part of the review.
Validation Status Review Process validation status confirmed current, with any validation-related activity from the period noted in the report.
Contractual and Outsourced Activity Review Quality performance of any contract manufacturers or laboratories involved in the product reviewed alongside internal data.
Previous Commitment Follow-Up Status of commitments made in the prior year's APR explicitly addressed, closing the loop on the review cycle.
Management Review Linkage APR conclusions summarized as an input to broader site or corporate management review meetings.

Never do this

Compile the APR without cross-referencing the prior year's report. Treat the annual review as a data compilation exercise without drawing an actual conclusion on state of control. Leave adverse trends without an assigned CAPA owner and timeline. Apply inconsistent event categorization that prevents genuine year-over-year comparison.

APR vs PQR

Annual Product Review is the FDA terminology under 21 CFR 211.180(e). Product Quality Review is the EU terminology under GMP Chapter 1. The two cover substantially overlapping ground, though the EU PQR framework specifies a somewhat more detailed and prescriptive list of required content elements.

Trending vs individual event review

Individual deviations, complaints, and OOS results are each investigated and closed on their own timeline throughout the year. The APR provides the separate, essential function of stepping back to see whether the aggregate pattern across an entire year reveals something no individual event review would surface.

Key regulations

21 CFR 211.180(e) - annual review requirement and content expectations. EU GMP Chapter 1 - Product Quality Review requirements. ICH Q10 - management review and continual improvement integration.